NovoCure Ltd (NVCR) - Product Pipeline Analysis, 2022 Update

Summary

NovoCure Ltd (NovoCure) is focused on the development and commercialization of novel delivery systems for the treatment of cancers of brain, thoracic and abdomen. Its proprietary Tumor Treating Fields (TTF) technology platform uses electric fields tuned to specific frequencies for disrupting the division of solid tumor cancer cells. The company markets TTF-based delivery systems: Optune Lua for the treatment of malignant pleural mesothelioma; and Optune for the treatment of glioblastoma. Both products are indicated in combination with standard chemotherapies. Its product development and clinical programs strive to improve the survival of patients suffering from pancreatic cancer, brain metastases, ovarian cancer, liver cancer, gastric cancer, and non-small cell lung cancer, among others. It has subsidiaries in Europe, the Middle East, Asia, and North America. NovoCure is headquartered in Saint Helier, Jersey, the UK.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company NovoCure Ltd
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company


NovoCure Ltd Company Overview
NovoCure Ltd Company Snapshot
NovoCure Ltd Pipeline Products and Ongoing Clinical Trials Overview
NovoCure Ltd – Pipeline Analysis Overview
Business Description
NovoCure Ltd - Key Facts
NovoCure Ltd - Major Products and Services
NovoCure Ltd Pipeline Products by Development Stage
NovoCure Ltd Ongoing Clinical Trials by Trial Status
NovoCure Ltd Pipeline Products Overview
Maxpoint Treatment Planning Software
Maxpoint Treatment Planning Software Product Overview
NovoTTF-100M System
NovoTTF-100M System Product Overview
NovoTTF-100M System Clinical Trial
NovoTTF-200A - Small Cell Lung Cancer
NovoTTF-200A - Small Cell Lung Cancer Product Overview
NovoTTF-200T - Advanced Non-Small Cell Lung Cancer
NovoTTF-200T - Advanced Non-Small Cell Lung Cancer Product Overview
Optune - Brain Metastasis
Optune - Brain Metastasis Product Overview
Optune - Brain Metastasis Clinical Trial
Optune - Breast Cancer
Optune - Breast Cancer Product Overview
Optune - Cervical Cancer
Optune - Cervical Cancer Product Overview
Optune - Colorectal Carcinoma
Optune - Colorectal Carcinoma Product Overview
Optune - Ependymoma
Optune - Ependymoma Product Overview
Optune - Gastric Adenocarcinoma
Optune - Gastric Adenocarcinoma Product Overview
Optune - Gastric Adenocarcinoma Clinical Trial
Optune - Gliosarcoma
Optune - Gliosarcoma Product Overview
Optune - Liver Cancer
Optune - Liver Cancer Product Overview
Optune - Malignant Melanoma
Optune - Malignant Melanoma Product Overview
Optune - Medulloblastoma
Optune - Medulloblastoma Product Overview
Optune - Meningioma
Optune - Meningioma Product Overview
Optune - Mesothelioma
Optune - Mesothelioma Product Overview
Optune - Non-Small Cell Lung Cancer
Optune - Non-Small Cell Lung Cancer Product Overview
Optune - Non-Small Cell Lung Cancer Clinical Trial
Optune - Ovarian Cancer
Optune - Ovarian Cancer Product Overview
Optune - Ovarian Cancer Clinical Trial
Optune - Pancreatic Cancer
Optune - Pancreatic Cancer Product Overview
Optune - Pancreatic Cancer Clinical Trial
Optune - Pediatric Glioma
Optune - Pediatric Glioma Product Overview
Optune - Pediatric Glioma Clinical Trial
Optune - Renal Adenocarcinoma
Optune - Renal Adenocarcinoma Product Overview
Optune - Small Cell Lung Cancer
Optune - Small Cell Lung Cancer Product Overview
Optune - Torso Array
Optune - Torso Array Product Overview
Optune - Torso Array Clinical Trial
Optune - Urinary Transitional Cell Carcinoma
Optune - Urinary Transitional Cell Carcinoma Product Overview
Optune Plus Bevacizumab - Recurrent Glioblastoma
Optune Plus Bevacizumab - Recurrent Glioblastoma Product Overview
Optune Plus Bevacizumab - Recurrent Glioblastoma Clinical Trial
Optune With Marizomib And Temozolomide - Glioblastoma
Optune With Marizomib And Temozolomide - Glioblastoma Product Overview
Optune With Pembrolizumab And Temozolomide
Optune With Pembrolizumab And Temozolomide Product Overview
Optune With Pembrolizumab And Temozolomide Clinical Trial
NovoCure Ltd - Key Competitors
NovoCure Ltd - Key Employees
NovoCure Ltd - Key Employee Biographies
NovoCure Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
NovoCure Ltd, Recent Developments
Apr 08, 2022: Novocure Announces 19 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2022 Suggesting Broad Applicability of Tumor Treating Fields
Feb 24, 2022: New data finds tumor treating fields initiates downstream anti-tumor response
Feb 24, 2022: Novocure Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update
Jan 10, 2022: Novocure Announces Preliminary Full Year and Fourth Quarter 2021 Net Revenues and Provides Company Update
Dec 06, 2021: Novocure announces 4th Annual AACR-Novocure grants for tumor treating fields research program
Oct 04, 2021: Zai Lab and Novocure announce last patient enrolled in phase 2 pilot trial of tumor treating fields plus chemotherapy as first-line treatment in gastric cancer in China
Jul 15, 2021: Novocure announces recipients of 3rd Annual AACR-Novocure grants for tumor treating fields research program
Apr 09, 2021: Novocure announces 26 presentations at American Association for Cancer Research (AACR) Annual Meeting 2021 Suggesting Broad Applicability of Tumor Treating Fields
Nov 10, 2020: Novocure announces agenda for Virtual Research and Development Day
Oct 29, 2020: Novocure announces strategic alliance with NYU Grossman School of Medicine for preclinical and clinical Research
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Table 1: NovoCure Ltd Pipeline Products and Ongoing Clinical Trials Overview
Table 2: NovoCure Ltd Pipeline Products by Equipment Type
Table 3: NovoCure Ltd Pipeline Products by Indication
Table 4: NovoCure Ltd, Key Facts
Table 5: NovoCure Ltd, Major Products and Services
Table 6: NovoCure Ltd Number of Pipeline Products by Development Stage
Table 7: NovoCure Ltd Pipeline Products Summary by Development Stage
Table 8: NovoCure Ltd Ongoing Clinical Trials by Trial Status
Table 9: NovoCure Ltd Ongoing Clinical Trials Summary
Table 10: Maxpoint Treatment Planning Software - Product Status
Table 11: Maxpoint Treatment Planning Software - Product Description
Table 12: NovoTTF-100M System - Product Status
Table 13: NovoTTF-100M System - Product Description
Table 14: NovoTTF-100M System - Pivotal, Open-label, Randomized Study of Radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-small Cell Lung Cancer (NSCLC)
Table 15: NovoTTF-100M System - Safety and Efficacy of SRS and Immune Checkpoint Inhibitors (ICI) Concurrent With NovoTTF-100M in Melanoma Brain Metastases
Table 16: NovoTTF-200A - Small Cell Lung Cancer - Product Status
Table 17: NovoTTF-200A - Small Cell Lung Cancer - Product Description
Table 18: NovoTTF-200T - Advanced Non-Small Cell Lung Cancer - Product Status
Table 19: NovoTTF-200T - Advanced Non-Small Cell Lung Cancer - Product Description
Table 20: Optune - Brain Metastasis - Product Status
Table 21: Optune - Brain Metastasis - Product Description
Table 22: Optune - Brain Metastasis - Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma
Table 23: Optune - Brain Metastasis - Prophylactic Tumor Treating Fields in Management of Patients with Small Cell Lung Cancer
Table 24: Optune - Breast Cancer - Product Status
Table 25: Optune - Breast Cancer - Product Description
Table 26: Optune - Cervical Cancer - Product Status
Table 27: Optune - Cervical Cancer - Product Description
Table 28: Optune - Colorectal Carcinoma - Product Status
Table 29: Optune - Colorectal Carcinoma - Product Description
Table 30: Optune - Ependymoma - Product Status
Table 31: Optune - Ependymoma - Product Description
Table 32: Optune - Gastric Adenocarcinoma - Product Status
Table 33: Optune - Gastric Adenocarcinoma - Product Description
Table 34: Optune - Gastric Adenocarcinoma - A Phase II Pilot Study of Tumor Treating Fields Together with Chemotherapy as First-line Treatment of Gastric Cancer
Table 35: Optune - Gliosarcoma - Product Status
Table 36: Optune - Gliosarcoma - Product Description
Table 37: Optune - Liver Cancer - Product Status
Table 38: Optune - Liver Cancer - Product Description
Table 39: Optune - Malignant Melanoma - Product Status
Table 40: Optune - Malignant Melanoma - Product Description
Table 41: Optune - Medulloblastoma - Product Status
Table 42: Optune - Medulloblastoma - Product Description
Table 43: Optune - Meningioma - Product Status
Table 44: Optune - Meningioma - Product Description
Table 45: Optune - Mesothelioma - Product Status
Table 46: Optune - Mesothelioma - Product Description
Table 47: Optune - Non-Small Cell Lung Cancer - Product Status
Table 48: Optune - Non-Small Cell Lung Cancer - Product Description
Table 49: Optune - Non-Small Cell Lung Cancer - A Pilot, Single Arm, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant with Pembrolizumab for First Line Treatment of Advanced or Metastatic Intrathoracic Non-Small Cell Lung Cancer: EF-36/Keynote B36
Table 50: Optune - Non-Small Cell Lung Cancer - Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent with Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure: LUNAR
Table 51: Optune - Non-Small Cell Lung Cancer - Prophylactic Tumor Treating Fields in Management of Patients with Small Cell Lung Cancer
Table 52: Optune - Non-Small Cell Lung Cancer - Study Evaluating the Safety and Efficacy of Tumor Treating Fields Together with KEYTRUDA (pembrolizumab) in Subjects with Non-small Cell Lung Cancer
Table 53: Optune - Ovarian Cancer - Product Status
Table 54: Optune - Ovarian Cancer - Product Description
Table 55: Optune - Ovarian Cancer - Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant with Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer: ENGOT-ov50 / GOG-3029 / INNOVATE-3
Table 56: Optune - Pancreatic Cancer - Product Status
Table 57: Optune - Pancreatic Cancer - Product Description
Table 58: Optune - Pancreatic Cancer - Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Table 59: Optune - Pediatric Glioma - Product Status
Table 60: Optune - Pediatric Glioma - Product Description
Table 61: Optune - Pediatric Glioma - A Phase I Trial of the Optune NovoTTF-200A System with Concomitant Temozolomide and Bevacizumab in Pediatric Patients with High-grade Glioma (HUMC 1612)
Table 62: Optune - Pediatric Glioma - Feasibility Trial of Optune for Children with Recurrent or Progressive Supratentorial High-grade Glioma and Ependymoma
Table 63: Optune - Renal Adenocarcinoma - Product Status
Table 64: Optune - Renal Adenocarcinoma - Product Description
Table 65: Optune - Small Cell Lung Cancer - Product Status
Table 66: Optune - Small Cell Lung Cancer - Product Description
Table 67: Optune - Torso Array - Product Status
Table 68: Optune - Torso Array - Product Description
Table 69: Optune - Torso Array - A Clinical Usability Study of Torso Array to Improve Patient Comfort for All Torso and Abdominal Indications
Table 70: Optune - Urinary Transitional Cell Carcinoma - Product Status
Table 71: Optune - Urinary Transitional Cell Carcinoma - Product Description
Table 72: Optune Plus Bevacizumab - Recurrent Glioblastoma - Product Status
Table 73: Optune Plus Bevacizumab - Recurrent Glioblastoma - Product Description
Table 74: Optune Plus Bevacizumab - Recurrent Glioblastoma - A Phase II Trial of Tumor Treating Fields (TTfields) Concomitant with Radiosurgery for the Treatment of Recurrent, Bevacizumab-naïve Glioblastoma
Table 75: Optune With Marizomib And Temozolomide - Glioblastoma - Product Status
Table 76: Optune With Marizomib And Temozolomide - Glioblastoma - Product Description
Table 77: Optune With Pembrolizumab And Temozolomide - Product Status
Table 78: Optune With Pembrolizumab And Temozolomide - Product Description
Table 79: Optune With Pembrolizumab And Temozolomide - Phase II, Single Arm, Historically Controlled Study Testing the Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune) Plus Pembrolizumab in Patients with Newly Diagnosed Glioblastoma (2-THE-TOP)
Table 80: NovoCure Ltd, Key Employees
Table 81: NovoCure Ltd, Key Employee Biographies
Table 82: NovoCure Ltd, Subsidiaries
Table 83: Glossary
List of Figures
Figure 1: NovoCure Ltd Pipeline Products by Equipment Type
Figure 2: NovoCure Ltd Pipeline Products by Development Stage
Figure 3: NovoCure Ltd Ongoing Clinical Trials by Trial Status

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings